0000000000542675

AUTHOR

Eleonora Cimini

0000-0002-2659-0868

showing 7 related works from this author

Myeloid-Derived Suppressor Cells Specifically Suppress IFN-γ Production and Antitumor Cytotoxic Activity of Vδ2 T Cells.

2018

γδ T cells represent less than 5% of circulating T cells; they exert a potent cytotoxic function against tumor or infected cells and secrete cytokines like conventional αβ T cells. As αβ T cells γδ T cells reside in the typical T cell compartments (the lymph nodes and spleen), but are more widely distributed in tissues throughout the body. For these reasons, some investigators are exploring the possibility of immunotherapies aimed to expand and activate Vδ2 T cells, or using them as Chimeric Antigen Receptor carriers. However, the role of immunosuppressive microenvironment on Vδ2 T cells during infections and cancers has not been completely elucidated. In particular, the effects of myeloid-…

0301 basic medicinelcsh:Immunologic diseases. AllergyCytotoxicity Immunologicγmedicine.medical_treatmentT cellδImmunologyAntitumoral activityT cellsSpleenLymphocyte ActivationJurkat cellsγδ T cellsImmunophenotyping03 medical and health sciencesInterferon-gamma0302 clinical medicineT-Lymphocyte SubsetsCell Line TumorNeoplasmsmedicineMyeloid-derived suppressor cellImmunology and AllergyCytotoxic T cellHumansIFN-γantitumoral activityArginaseChemistryMyeloid-Derived Suppressor CellsDegranulationReceptors Antigen T-Cell gamma-deltaImmunotherapy030104 developmental biologymedicine.anatomical_structureCell cultureCancer researchMyeloid-derived Suppressor CellLeukocytes MononuclearCytokinesImmunotherapyimmunotherapylcsh:RC581-607Biomarkers030215 immunologyFrontiers in immunology
researchProduct

COVID-19 in people living with HIV: Clinical implications of dynamics of the immune response to SARS-CoV-2.

2020

ABSTRACT Background Little evidence on COVID‐19 in people living with HIV (PLWH) is currently available. Material and Methods We reported clinical and viro‐immunological data of all HIV‐positive patients admitted to our centre with COVID‐19 from March 1 to May 12,2020. Results Overall, five patients were included: all were virologically‐suppressed on antiretroviral therapy and CD4+ count was >350 cell/mm3 in all but two patients. Although all patients had evidence of pneumonia on admission, only one developed respiratory failure. SARS‐CoV‐2‐RNA was never detected from nasopharyngeal swabs in two patients, whereas, in the others, viral clearance occurred within a maximum of 43 days. IgG prod…

Malemedicine.medical_treatmentHIV InfectionsAntibodies ViralSeverity of Illness IndexImmunoglobulin GPiperazinesimmune responseSARS‐CoV‐20302 clinical medicine030212 general & internal medicinebiologyCoinfectionImmunosuppressionMiddle AgedInfectious DiseasesAnti-Retroviral AgentsCytokinesRNA ViralReverse Transcriptase Inhibitors030211 gastroenterology & hepatologyFemaleAntibodyHeterocyclic Compounds 3-RingRiskPyridonesShort CommunicationShort CommunicationsTransgender PersonsProinflammatory cytokine03 medical and health sciencesImmune systemCOVID‐19VirologySeverity of illnessOxazinesmedicineHumansHIV Integrase InhibitorsTenofovirbusiness.industrySARS-CoV-2medicine.diseaseHIV infectionVirologyAntibodies NeutralizingCD4 Lymphocyte CountImmunity HumoralCOVID-19 Drug TreatmentPneumoniaRespiratory failureImmunologybiology.proteinbusinessJournal of medical virology
researchProduct

The unbalanced p53/SIRT1 axis may impact lymphocyte homeostasis in COVID-19 patients

2021

Abstract Background/objectives A dysregulated inflammatory profile plays an important role in coronavirus disease-2019 (COVID-19) pathogenesis. Moreover, the depletion of lymphocytes is typically associated with an unfavourable disease course. We studied the role and impact of p53 and deacetylase Sirtuin 1 (SIRT1) on lymph-monocyte homeostasis and their possible effect on T and B cell signalling. Methods Gene expression analysis and flow cytometry were performed on peripheral blood mononuclear cells (PBMC) of 35 COVID-19 patients and 10 healthy donors (HD). Inflammatory cytokines, the frequency of Annexin+ cells among CD3+ T cells and CD19+ B cell subsets were quantified. Results PBMC from …

0301 basic medicineMicrobiology (medical)Male030106 microbiologyInflammationInfectious and parasitic diseasesRC109-216CD19ArticleProinflammatory cytokineBLNK Inflammation03 medical and health sciences0302 clinical medicineSirtuin 1Lymphocyte homeostasismedicineHomeostasisHumans030212 general & internal medicineLymphocytesInterleukin-7 receptorB cellAgedInflammationBLNKbiologySirtuin 1SARS-CoV-2COVID-19p53/SIRT1General MedicineIL-7RMiddle Agedmedicine.anatomical_structureInfectious DiseasesSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICABLNK; COVID-19; IL-7R; inflammation; p53/SIRT1ImmunologyB-cell linkerbiology.proteinCytokinesFemalemedicine.symptomTumor Suppressor Protein p53
researchProduct

An Inflammatory Profile Correlates With Decreased Frequency of Cytotoxic Cells in Coronavirus Disease 2019

2020

Abstract Increased production of inflammatory cytokines and myeloid-derived suppressor cells occurs in patients with coronavirus disease 2019. These inversely correlated with perforin-expressing natural killer (NK) and CD3+ T cells. We observed a lower number of perforin-expressing NK cells in intensive care unit (ICU) patients compared with non-ICU patients, suggesting an impairment of the immune cytotoxic arm as a pathogenic mechanism.

0301 basic medicineMicrobiology (medical)medicine.medical_treatmentMDSCInflammationchemical and pharmacologic phenomenaNK cellsProinflammatory cytokineNatural killer cell03 medical and health sciences0302 clinical medicineImmune systemmedicineCytotoxic T cellcytotoxic cellcytotoxic cellsbiologybusiness.industryCOVID-19COVID-19; cytotoxic cells; inflammation; MDSC; NK cells030104 developmental biologymedicine.anatomical_structureCytokineInfectious DiseasesPerforinSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAinflammation030220 oncology & carcinogenesisImmunologybiology.proteinMyeloid-derived Suppressor Cellmedicine.symptombusinessClinical Infectious Diseases
researchProduct

GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults

2022

International audience; Safe and effective vaccines against coronavirus disease 2019 (COVID-19) are essential for ending the ongoing pandemic. Although impressive progress has been made with several COVID-19 vaccines already approved, it is clear that those developed so far cannot meet the global vaccine demand alone. We describe a COVID-19 vaccine based on a replication-defective gorilla adenovirus expressing the stabilized prefusion severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein named GRAd-COV2. We assessed the safety and immunogenicity of a single-dose regimen of this vaccine in healthy younger and older adults to select the appropriate dose for each age group…

2019-20 coronavirus outbreakCOVID-19 VaccinesSettore BIO/06Coronavirus disease 2019 (COVID-19)COVID-19 VaccineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)GorillaAdenoviridaeAdenovirus Vaccinesbiology.animalPandemicAnimalsHumansMedicineMESH: COVID-19MESH: AnimalsMESH: SARS-CoV-2AgedMESH: Adenovirus VaccinesMESH: AgedGorilla gorilla[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyMESH: HumansbiologyAnimalSARS-CoV-2business.industryMESH: Gorilla gorillaCOVID-19MESH: AdenoviridaeGeneral MedicineVirologyAdenovirus VaccineMESH: COVID-19 Vaccinesbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyHuman
researchProduct

GRAd-COV2, a gorilla adenovirus based candidate vaccine against COVID-19, is safe and immunogenic in young and older adults

2021

AbstractSafe and effective vaccines against coronavirus disease 2019 (COVID-19) are urgently needed to control the ongoing pandemic. Although impressive progress has been made with several COVID-19 vaccines already approved, it is clear that those developed so far cannot meet the global vaccine demand. We have developed a COVID-19 vaccine based on a replication-defective gorilla adenovirus expressing the stabilized pre-fusion SARS-CoV-2 Spike protein, named GRAd-COV2. We aimed to assess the safety and immunogenicity of a single-dose regimen of this vaccine in healthy younger and older adults to select the appropriate dose for each age group. To this purpose, a phase 1, dose-escalation, open…

Pediatricsmedicine.medical_specialtybiologybusiness.industryImmunogenicityGorillaVaccinationRegimenAntigenbiology.animalPandemicbiology.proteinmedicineAntibodySeroconversionbusiness
researchProduct

Different Innate and Adaptive Immune Responses to SARS-CoV-2 Infection of Asymptomatic, Mild, and Severe Cases

2020

Abstract Background SARS-CoV-2 is a novel coronavirus, not encountered before by humans. The wide spectrum of clinical expression of SARS-CoV-2 illness suggests that individual immune responses to SARS-CoV-2 play a crucial role in determining the clinical course after first infection. Immunological studies have focussed on patients with moderate to severe disease, demonstrating excessive inflammation in tissues and organ damage. We have studied the individual response to SARS-CoV-2 of asympromatic, mild and severe COVID-19 patients in order to investigate the role of innnate and adaptive immunity in determining the clinical course after first infection. Methods To understand the basis of th…

0301 basic medicineAdultMalelcsh:Immunologic diseases. AllergyImmunologyInflammationDiseaseAdaptive Immunitymedicine.disease_causeAntibodies ViralAsymptomaticSeverity of Illness IndexSerology03 medical and health sciences0302 clinical medicineImmune systeminnate and adaptiveimmune responsemedicineHumansImmunology and AllergyantibodiesNK cellOriginal ResearchCoronavirusB cellsbiologybusiness.industrySARS-CoV-2MonocyteSettore BIO/12COVID-19antibodies; B cells; COVID-19; innate and adaptiveimmune response; monocytes; NK cell; SARS-CoV-2Acquired immune systemImmunity InnateImmunoglobulin AKiller Cells Natural030104 developmental biologymedicine.anatomical_structureImmunoglobulin MSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA030220 oncology & carcinogenesisImmunologybiology.proteinFemalemedicine.symptomAntibodybusinesslcsh:RC581-607monocytes
researchProduct